※ 当資料は英文にてご提供いたします。

Abstract

A comprehensive update of the 2005 edition

The report estimates that the current market for addiction disorders is valued at US$3.2 billion and this is forecast to increase 19% to US$3.8 billion by 2016.

Examines the market for addiction pharmacotherapies currently estimated at US$2 billion

The substance dependence field is transforming into a high-growth market opportunity. Supported by the success of Pfizer' s recently launched Chantix/Champix, which is on track for blockbuster status in the smoking cessation sector, pharmacotherapies in development for alcohol, narcotic, and nicotine dependencies are poised to radically change the addiction treatment landscape in this difficult-to-treat patient population.

The report estimates that the current market for addiction disorders is valued at US$3.2 billion and this is forecast to increase 19% to US$3.8 billion by 2016.

The World Market for Addiction Disorders, 2009 2016: Future Therapies for Substance Dependence and Impulse Control, will introduce the reader a specialty pharmaceutical market which is positioned for high-growth based on analysis of marketed and pipeline drugs, company activities, and addiction disorder demographics.

Therapy area forecasting and illustrative comparative sales data is presented to gain insight into leading products with sales estimates to 2016.

Objectives of Report

The objectives of this 80 page report are to provide an in-depth analysis of the global addiction pharmacotherapeutic market. Included in this study are analyses of key therapy areas, R&D programs, and innovating companies and products. The reader will benefit from market forecasts, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate growth and create new market opportunities.

Report Highlights Include:

• The current market for addiction disorders is valued at US$3.2 billion, up from US$2 billion in 2005
• Critical analysis of alcohol, cocaine, opiate, and nicotine addictions
• Review of epidemiological, aetiological, and demographic data for addiction disorders
• Analysis of over 10 key marketed products and inclusion of 34 R&D candidates identified in preclinical to clinical stages of development for addiction disorders
• Sales estimates (US$) to 2012 for major therapy areas
• Strategic insights for life-cycle optimization and product development
• Critical evaluation of leading addiction pharmacotherapies
• Emerging markets identified and sector analysis
• Trend analysis of industry events and activities over past 2 years
• Detailed R&D themes and clusters by addiction area
• Data generation on sector and market values between 2004 and 2012 and therapy forecasts by 2020 (US$)
• High revenue-yielding prospects identified with projected sales estimations
• R&D pipeline positioning for novel candidates
• Market insights for product development and drug promotion

What you can learn from this report:

• Which addiction therapies are the current and potential future market leaders
• How companies are reformulating products for addiction indications
• Which premarket addiction pharmacotherapies are identified as high-value products
• Which companies are developing drugs for addiction disorders
• Sales predictions to 2016 for addiction pharmacotherapies
• What the likely impact of pipeline products will be on value growth of the addiction market over the 10 years
• Which addiction subsectors could be niche market opportunities
• What the future outlook holds for addiction pharmacotherapies
• Insight into R&D trends for alcohol, cocaine, opiate, and nicotine addictions
• Which molecules and compounds are main R&D clusters for dependency disorders
• Which of the pipeline candidates are top prospects in the addiction market over the next decade and to 2025

Report Contains:

• Detailed survey and analysis of the current and future global addiction disorder market
• Comprehensive update on key marketed products indicated for alcohol, narcotic, and nicotine dependency disorders
• Review of epidemiological, demographic, aetiological, and therapeutic data associated with addiction disorders
• Market analysis and insight of key addiction pharmacotherapies and pipelines
• Market value predictions of individual marketed products to 2016
• Insight and trend analysis of pipeline products for addiction disorders
• Review of promising pipeline products and potential market opportunities
• Extensive coverage of the R&D pipeline for addiction disorders
• Guide to leads for potential licensing opportunities

Table of Contents

Chapter 1. Introduction to Addiction Disorders

• Addiction: Substance Characteristics and Prevalence of Misuse
• Neurobiological Basis of Addiction
• Prevalence of Substance Misuse - Estimates for North America, Europe and Asia
  • North America
  • United States
  • Canada
  • Europe
  • Asia (Japan)

• Incidence Estimates for Addiction Disorders in North America, Europe, and Japan
• Treatment Options

Chapter 2. The Addiction Pharmacotherapy Market

• Market Overview for Addiction Disorders
• Market Forecasts by Therapeutic Area
  • Alcohol Addiction
  • Narcotic Addiction
  • Tobacco Addiction

Chapter 3. Alcohol Addiction Market

• Alcohol Addiction
  • Acamprosate (Campral) - Merck Serono/Forest Laboratories
  • Disulfiram (Antabuse) - Alpharma
  • Naltrexone Hydrochloride
  • Alkermes - Reformulated Naltrexone (Vivitrol)
• Pipeline Focus for Alcohol Addiction - Biotie Therapies Corp
  • Nalmefene
  • Naltrexone Depot
• Alcohol Addiction - Market Insights and Future Considerations

Chapter 4. The Narcotic Addiction Market

• Global Narcotics - Usage Statistics
• Narcotic Addiction - The Scale of the Problem
• Pharmacotherapies for Narcotic Addiction - Market Evaluation
• Opioid Addiction Pharmacotherapies
  • Drug Substitute Therapies
  • Subutex/Suboxone (Buprenorphine) - Schering-Plough/Reckitt Benckiser
  • Suboxone Reformulation
  • Methadone
• Drugs to Control Opioid Withdrawal Symptoms
  • BritLofex (Lofexidine); Opizone (Naltrexone) - Britannia Pharma/STADA
  • Naltrexone
  • Nalorex - Bristol-Myers Squibb
  • Opizone - Britannia
• Therapeutic Switching in Addiction Markets
• Outlook for Pharmacotherapeutic Markets Related to Alcohol and Narcotic Abuse

Chapter 5. Tobacco Addiction

• Prevalence and Mortality Statistics
• Nicotine: Mechanism of Action
• Tobacco Dependence and Smoking Cessation
• Smoking and Health Consequences
  • Healthcare Costs of Smoking Addiction
• Tobacco Addiction Pharmacotherapeutics
• Market Analysis of Smoking Cessation Pharmacotherapeutics
• Nicotine Replacement Therapies
• Nicorette/Nicotrol - McNeil Healthcare/Johnson & Johnson
• Sales Estimates
  • NiQuitin/NicoDerm/Nicorette/Nicabate - GlaxoSmithKline
  • Sales Estimates
  • Nicotinell/Habitrol - Novartis
  • Sales Estimates
  • Neuromodulating Pharmacotherapies for Smoking Cessation
  • Zyban (Bupropion) - GlaxoSmithKline
  • Sales Estimates
  • Champix/Chantix (Varenicline) - Pfizer
  • Sales Estimates
• Tobacco Addiction - Market Insights and Future Considerations

Chapter 6. Drugs in Research and Development

• Addiction Disorders - Research and Development Overview
• Pipeline Addiction Pharmacotherapies
• Alcohol Dependence
• Cocaine Dependence
• Novel Late-Stage Candidates
  • Celtic Pharmaceuticals
  • Synosia Therapeutics/Roche
  • Cannabis Dependence
  • Immunotherapy Focus - InterveXion Therapeutics
• Opioid Dependence
  • Late-Stage Development Products for Opioid Dependence
• Impulse Control Disorders
• Pipeline Focus - Gambling Addiction
• Tobacco/Nicotine Dependence
• Pipeline Focus on Immunotherapies for Tobacco Dependence
  • Nabi Biopharmaceuticals - NicVAX
  • Celtic Pharmaceuticals - TA-NIC
• Smoking Cessation - A Transforming Market

Chapter 7. Market Analysis, Therapy Forecasting, and Prospect Mining

• Market Analysis and Therapy Forecasting
• Therapy Area Forecasts
  • Comparative Analysis: Addiction Pharmacotherapies
• Prospect Mining
  • Addiction Disorder Pharmacotherapy Prospects
• Therapy Area Forecasts 2016 and 2025

Chapter 8. Summary and Key Data Points on the Addiction Market

• Key Data Points
• Reference Sources

List of Tables

• Table 1.1: Neurotransmitter Systems Associated with Addiction
• Table 1.2: Drugs of Abuse and their Associations with Neurotransmitter Systems
• Table 1.3: Estimated Prevalence of Substance Misuse in Europe, 2009 (000' users)
• Table 1.4: Estimated Incidence for Addiction Disorders in North America, Europe and Japan, 2009 (incidence in 000s)
• Table 2.1: Market Synopsis for Addiction Disorders: Current data
• Table 2.2: Estimated Global Sales (US$) and Annual Growth (%) of Key Drugs to Treat Addictions, 2008-2016
• Table 3.1: Physiological Consequences of the Disulfiram-Alcohol Reaction
• Table 5.1: Estimated Sales (US$) and Annual Growth (%) of Smoking Cessation Therapies, 2008-2016
• Table 6.1: Drugs in Development/Trials for Alcohol Dependence, 2009
• Table 6.2: Drugs in Development/Trials for Cocaine Dependence, 2009
• Table 6.3: Drugs in Development/Trials for Cannabis Dependence, 2009
• Table 6.4: Drugs in Development/Trials for Ampetamine and Phencyclidine Dependencies, 2009
• Table 6.5: Drugs in Development/Trials for Opioid Dependence, 2009
• Table 6.6: Drugs in Development/Trials for Impulse Control Disorders, 2009
• Table 6.7: Drugs in Development/Trials for Tobacco Addiction, 2009
• Table 7.1: Estimated Global Drug Market (US$m) and Growth Rate (%) for Addiction Pharmacotherapies, 2008-2016
• Table 7.2: Therapy Area Forecasts for the World Addiction Disorders Market, 2016 and 2025

List of Figures

• Figure 1.1: Estimated Prevalence of Substance Misuse in United States, 2009
• Figure 1.2: stimated Prevalence of Substance Misuse in Canada, 2009
• Figure 1.3: Estimated Prevalence of Substance Misuse in Europe, 2009
• Figure 1.4: Estimated Prevalence of Substance Misuse in Japan, 2009
• Figure 2.1: Estimated Sales (US$) of Addiction Drugs Segmented by Therapeutic Area, 2008-2016
• Figure 2.2: Estimated Global Sales (US$) of Leading Addiction Drugs by Therapy Area, 2009 & 2016
• Figure 7.1: Comparative Analysis of Leading Addiction Pharmacotherapies, 2008-2016 (US$m)
• Figure 7.2: Key Addiction Disorder Pharmacotherapy Prospects, 2009

Companies Mentioned Include:

• Acrux
• Alkermes
• Biotie Therapies
• Brookwood Pharmaceuticals
• Catalyst Pharma Partners
• Celtic Pharmaceuticals
• Cephalon
• Drug Abuse Sciences
• Elbion
• Eli Lilly
• Forest Laboratories
• GlaxoSmithKline
• Impax Laboratories
• InterveXion Therapeutics
• J&J
• Janssen-Cilag
• Krele Pharma
• Merck Serono
• Nabi Biopharmaceuticals
• Nabi Biopharmaceuticals
• Pfizer
• Sanofi-Aventis
• Somaxon
• Somaxon Pharma.
• STADA
• Synosia Therapeutics/Roche
• Synosia Therarapeutics
• Targacept
• Teva Pharmaceuticals
• Titan Pharmaceuticals
• WorldMeds
• Yaupon Therapeutics